Abbott Labs Q1 top line flat, net income off 86%, GAAP EPS guidance lowered; shares up 1% premarket on consensus beat

• Abbott Laboratories (NYSE:ABT) Q1 results ($M): Total Revenues: 4,885 (-0.2%); Nutrition: 1,671 (+0.1%); Diagnostics: 1,118 (+2.3%); Est. Pharmaceuticals: 888 (-1.0%); Medical Devices: 1,197 (-2.4%).
• Net Income: 316 (-86.2%); EPS: 0.21 (-86.1%); Non-GAAP EPS (continuing ops): 0.41 (-12.8%).
• 2016 Guidance: EPS: $1.36 - 1.46 from $1.55 - 1.65; Non-GAAP EPS: $2.14 - 2.16 from $2.10 to 2.20.
• The consensus view was EPS of $0.39 on revenues of $4.8B.
• Read now Why Long-Term Investors Should Consider Abbott Laboratories